NFA
CNCE

Nationwide Fund Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Nationwide Fund Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9,861
Closed -$145K – 2390
2017
Q3 		$145K Hold
9,861
– – ﹤0.01% 2763
2017
Q2 		$138K Hold
9,861
– – ﹤0.01% 2770
2017
Q1 		$168K Sell
9,861
-7,506
-43% -$90K ﹤0.01% 2663
2016
Q4 		$179K Sell
17,367
-19,083
-52% -$174K ﹤0.01% 2660
2016
Q3 		$369K Sell
36,450
-970
-3% -$10.6K ﹤0.01% 2324
2016
Q2 		$420K Buy
37,420
+322
+0.9% +$4.1K ﹤0.01% 2240
2016
Q1 		$507K Buy
37,098
+26,900
+264% +$387K ﹤0.01% 2087
2015
Q4 		$193K Buy
10,198
+313
+3% +$6.8K ﹤0.01% 2577
2015
Q3 		$186K Hold
9,885
– – ﹤0.01% 2598
2015
Q2 		$147K Buy
+9,885
New +$151K ﹤0.01% 2877
2014
Q2 		– Sell
-14,746
Closed -$198K – 3400
2014
Q1 		$198K Buy
+14,746
New +$208K ﹤0.01% 2490

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Nationwide Fund Advisors's CNCE Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2017, closing a stake of 9,861 shares — an estimated $145K sold.

Nationwide Fund Advisors first reported a position in CNCE in Q1 2014 and held it in 11 quarters. The position peaked at $507K in Q1 2016. 114 funds tracked by Wall St. Rank hold CNCE as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 9,861 Concert Pharmaceuticals, Inc. shares in Q4 2017, an estimated $145K.
  • Nationwide Fund Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 11 quarters.
  • Nationwide Fund Advisors's Concert Pharmaceuticals, Inc. position peaked at $507K in Q1 2016.
  • 114 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.